Edition:
United States

Celltrion Inc (068270.KQ)

068270.KQ on KOSDAQ - Korea Secs Dealers Association Quotation

89,800.00KRW
24 Mar 2017
Change (% chg)

₩1,700.00 (+1.93%)
Prev Close
₩88,100.00
Open
₩88,700.00
Day's High
₩89,800.00
Day's Low
₩87,400.00
Volume
860,745
Avg. Vol
425,024
52-wk High
₩116,190.00
52-wk Low
₩83,904.80

Latest Key Developments (Source: Significant Developments)

Celltrion to buy back shares at 45.75 bln won
Tuesday, 21 Mar 2017 04:08am EDT 

Celltrion Inc <068270.KQ> : Says it will repurchase 500,000 common shares . Says repurchase amount is 45.75 billion won .Says repurchase period from March 22 to June 21.  Full Article

Celltrion signs contract worth 56.8 bln won
Thursday, 23 Feb 2017 02:46am EST 

Celltrion Inc <068270.KQ> :Says it signed a 56.8 billion won contract with Celltrion Healthcare co.,Ltd to sell bio-similar antibody drug.  Full Article

Celltrion signs contract worth 53.25 bln won
Wednesday, 25 Jan 2017 09:23pm EST 

Celltrion Inc <068270.KQ> :Says it signed a 53.25 billion won contract with Celltrion Healthcare co.,Ltd, to sell antibody drug.  Full Article

Celltrion receives patent
Monday, 9 Jan 2017 12:10am EST 

Celltrion Inc <068270.KQ> :Says it receives patent about human monoclonal antibody, on Jan. 9.  Full Article

Celltrion signs 149.10 bln won contract with Celltrion Healthcare
Wednesday, 21 Dec 2016 02:45am EST 

Celltrion Inc <068270.KQ> : Says it signs 149.10 billion won contract with Celltrion Healthcare to sell remsima .Says the contract period from Dec. 21 to Dec. 31.  Full Article

Celltrion says annual stock dividend for 2016
Tuesday, 20 Dec 2016 08:40pm EST 

Celltrion Inc <068270.KQ> : Says it will distribute annual stock dividend of 0.05 new shares for each existing share . Says new shares of total distribution amount is 5.8 million .Says dividend distribution date is Dec. 31.  Full Article

Teva and Celltrion report exclusive biosimilar commercial partnership
Thursday, 6 Oct 2016 08:00am EDT 

Teva Pharmaceutical Industries Ltd : Teva will pay Celltrion healthcare $160 million upfront . Teva and Celltrion healthcare will share profit from commercialization of mab biosimilars . Exclusive partnership to commercialize two of Celltrion's MAB biosimilar candidates in U.S. and canada . Celltrion has responsibility for completing all clinical development and regulatory activities .Of $160 million upfront payment, up to $60 million is refundable or creditable under certain circumstances.  Full Article

Celltrion receives patent
Monday, 29 Aug 2016 03:40am EDT 

Celltrion Inc <068270.KQ> :Says it receives patent on Aug. 29, for human monoclonal antibody generated from human B-cells able to neutralize influenza A viruses.  Full Article

Johnson & Johnson announces ruling related to Remicade
Wednesday, 17 Aug 2016 01:54pm EDT 

Johnson & Johnson : Johnson & Johnson announces ruling related to Remicade in the District of Massachusetts Federal Court hearing . Janssen is also continuing appeal process in proceedings related to 471 patent before U.S. Patent & Trademark office . Commercial launch of an infliximab biosimilar prior to outcome of appeals would be considered an at-risk launch .Reaffirms its sales guidance for operational sales growth for FY 2016 of 3 pct to 4 pct, notwithstanding possibility of a biosimilar launch on or after Oct. 3, 2016.  Full Article

Celltrion, signs contract with Celltrion Healthcare
Wednesday, 23 Mar 2016 03:15am EDT 

Celltrion, Inc:Signs contract with Celltrion Healthcare co.,Ltd, to supply biosimilars antibody drug.Contract amount of 85,200 mln won.  Full Article

More From Around the Web

BRIEF-Celltrion to buy back shares at 45.75 bln won

March 21 Celltrion Inc : * Says it will repurchase 500,000 common shares * Says repurchase amount is 45.75 billion won * Says repurchase period from March 22 to June 21 Source text in Korean: https://goo.gl/OM5dJX Further company coverage: (Beijing Headline News)